Cutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis

Inflamm Bowel Dis. 2021 Jan 19;27(2):e15-e17. doi: 10.1093/ibd/izaa255.
No abstract available

Keywords: adverse events; biological therapy; ulcerative colitis; vedolizumab.

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Colitis, Ulcerative* / drug therapy
  • Gastrointestinal Agents / adverse effects*
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Vasculitis / chemically induced*

Substances

  • Antibodies, Monoclonal, Humanized
  • Gastrointestinal Agents
  • vedolizumab